Moleculin Reveals Final Topline Data From European Study Of Annamycin In Leukemia Setting
Moleculin Biotech Inc (NASDAQ:MBRX) announced the topline results from its MB-105 European Phase 1 clinical trial assessing the safety and efficacy…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Novo Integrated Sciences (NASDAQ:NVOS) stock rose 44.2% to $0.29 during Monday’s after-market session. At the close, Novo…
Moleculin Biotech’s Annamycin In Leukemia Study Shows 80% Overall Response Rate
Moleculin Biotech Inc (NASDAQ:MBRX) provided an update on its clinical programs evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML)…
Moleculin Granted FDA Fast Track Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,
Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower by around 500 points on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Gainers
Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash.
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.
Moleculin Provides Update On Second Multiple Ascending Dose (MAD) Cohort In Phase 1a Clinical Trial Of WP1122 In UK; Shares Move Lower
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors
Moleculin Biotech’s Potential Antiviral Compound Selected For NIAID-Funded Animal Studies
Moleculin Biotech Inc (NASDAQ:MBRX) announced that its WP1096 molecule would be evaluated in animal studies by the National Institute of Allergy…